|
1
|
Smith RA, Andrews KS, Brooks D, Fedewa SA,
Manassaram-Baptiste D, Saslow D and Wender RC: Cancer screening in
the United States, 2019: A review of current American cancer
society guidelines and current issues in cancer screening. CA
Cancer J Clin. 69:184–210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Skibinski A and Kuperwasser C: The origin
of breast tumor heterogeneity. Oncogene. 34:5309–5316. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang L, Gallo KA and Conrad SE: Targeting
mixed lineage kinases in ER-positive breast cancer cells leads to
G2/M cell cycle arrest and apoptosis. Oncotarget. 4:1158–1171.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sommer S and Fuqua SA: Estrogen receptor
and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slamon D, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Montagna E, Maisonneuve P, Rotmensz N,
Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini
A, Pruneri G, et al: Heterogeneity of triple-negative breast
cancer: Histologic subtyping to inform the outcome. Clin Breast
Cancer. 13:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zuo T, Wang L, Morrison C, Chang X, Zhang
H, Li W, Liu Y, Wang Y, Liu X, Chan MWY, et al: FOXP3 is an
X-linked breast cancer suppressor gene and an important repressor
of the HER-2/ErbB2 oncogene. Cell. 184:63782021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto S, Wu Z, Russnes HG, Takagi S,
Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB,
et al: JARID1B is a luminal lineage-driving oncogene in breast
cancer. Cancer Cell. 25:762–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Tognon CE, Godinho FJ, Yasaitis L,
Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, et
al: ETV6-NTRK3 fusion oncogene initiates breast cancer from
committed mammary progenitors via activation of AP1 complex. Cancer
Cell. 12:542–558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dreyfuss G, Kim VN and Kataoka N:
Messenger-RNA-binding proteins and the messages they carry. Nat Rev
Mol Cell Biol. 3:195–205. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell SF and Parker R: Principles and
properties of eukaryotic mRNPs. Mol Cell. 54:547–558. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang ZJ, Li B, Luo YX, Lin Q, Liu SR,
Zhang XQ, Zhou H, Yang JH and Qu LH: Comprehensive genomic
characterization of RNA-binding proteins across human cancers. Cell
Rep. 22:286–298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith CW and Valcárcel J: Alternative
pre-mRNA splicing: The logic of combinatorial control. Trends
Biochem Sci. 25:381–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marcotrigiano J, Gingras AC, Sonenberg N
and Burley SK: Cocrystal structure of the messenger RNA 5′
cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell.
89:951–961. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saulière J, Murigneux V, Wang Z, Marquenet
E, Barbosa I, Le Tonquèze O, Audic Y, Paillard L, Roest Crollius H
and Le Hir H: CLIP-seq of eIF4AIII reveals transcriptome-wide
mapping of the human exon junction complex. Nat Struct Mol Biol.
19:1124–1131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gehring NH, Lamprinaki S, Kulozik AE and
Hentze MW: Disassembly of exon junction complexes by PYM. Cell.
137:536–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ali MAM: DEAD-box RNA helicases: The
driving forces behind RNA metabolism at the crossroad of viral
replication and antiviral innate immunity. Virus Res.
296:1983522021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: A new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Palacios IM, Gatfield D, St Johnston D and
Izaurralde E: An eIF4AIII-containing complex required for mRNA
localization and nonsense-mediated mRNA decay. Nature. 427:753–757.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shibuya T, Tange TØ, Sonenberg N and Moore
MJ: eIF4AIII binds spliced mRNA in the exon junction complex and is
essential for nonsense-mediated decay. Nat Struct Mol Biol.
11:346–351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ito M, Tanaka T, Cary DR,
Iwatani-Yoshihara M, Kamada Y, Kawamoto T, Aparicio S, Nakanishi A
and Imaeda Y: Discovery of novel 1,4-diacylpiperazines as selective
and cell-active eIF4A3 inhibitors. J Med Chem. 60:3335–3351. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin Y, Zhang J, Cai J, Liang R, Chen G,
Qin G, Han X, Yuan C, Liu Z, Li Y, et al: Systematic analysis of
gene expression alteration and co-expression network of eukaryotic
initiation factor 4A-3 in cancer. J Cancer. 9:4568–4577. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitchell JP and Carmody RJ: NF-κB and the
transcriptional control of inflammation. Int Rev Cell Mol Biol.
335:41–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Waskiewicz AJ, Johnson JC, Penn B,
Mahalingam M, Kimball SR and Cooper JA: Phosphorylation of the
cap-binding protein eukaryotic translation initiation factor 4E by
protein kinase Mnk1 in vivo. Mol Cell Biol. 19:1871–1880. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fukunaga R and Hunter T: MNK1, a new MAP
kinase-activated protein kinase, isolated by a novel expression
screening method for identifying protein kinase substrates. EMBO J.
16:1921–1933. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wheater MJ, Johnson PW and Blaydes JP: The
role of MNK proteins and eIF4E phosphorylation in breast cancer
cell proliferation and survival. Cancer Biol Ther. 10:728–735.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robichaud N, del Rincon SV, Huor B, Alain
T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH,
Furic L, et al: Phosphorylation of eIF4E promotes EMT and
metastasis via translational control of SNAIL and MMP-3. Oncogene.
34:2032–2042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robichaud N, Hsu BE, Istomine R, Alvarez
F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, et
al: Translational control in the tumor microenvironment promotes
lung metastasis: Phosphorylation of eIF4E in neutrophils. Proc Natl
Acad Sci USA. 115:E2202–E2209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chrestensen CA, Shuman JK, Eschenroeder A,
Worthington M, Gram H and Sturgill TW: MNK1 and MNK2 regulation in
HER2-overexpressing breast cancer lines. J Biol Chem.
282:4243–4252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Evans MK, Brown MA, Geradts J, Bao X,
Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine
H, et al: XIAP regulation by MNK links MAPK and NFκB signaling to
determine an aggressive breast cancer phenotype. Cancer Res.
78:1726–1738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma WJ, Cheng S, Campbell C, Wright A and
Furneaux H: Cloning and characterization of HuR, a ubiquitously
expressed Elav-like protein. J Biol Chem. 271:8144–8151. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kotta-Loizou I, Giaginis C and Theocharis
S: Clinical significance of HuR expression in human malignancy. Med
Oncol. 31:1612014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ortega AD, Sala S, Espinosa E,
González-Barón M and Cuezva JM: HuR and the bioenergetic signature
of breast cancer: A low tumor expression of the RNA-binding protein
predicts a higher risk of disease recurrence. Carcinogenesis.
29:2053–2061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu F, Zhang X, Lei Y, Liu X, Liu Z, Tong T
and Wang W: Loss of repression of HuR translation by miR-16 may be
responsible for the elevation of HuR in human breast carcinoma. J
Cell Biochem. 111:727–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heinonen M, Hemmes A, Salmenkivi K,
Abdelmohsen K, Vilén ST, Laakso M, Leidenius M, Salo T, Hautaniemi
S, Gorospe M, et al: Role of RNA binding protein HuR in ductal
carcinoma in situ of the breast. J Pathol. 224:529–539. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stylianou S, Clarke RB and Brennan K:
Aberrant activation of notch signaling in human breast cancer.
Cancer Res. 66:1517–1525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chae MJ, Sung HY, Kim EH, Lee M, Kwak H,
Chae CH, Kim S and Park WY: Chemical inhibitors destabilize HuR
binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med.
41:824–831. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Izquierdo JM: Hu antigen R (HuR) functions
as an alternative pre-mRNA splicing regulator of Fas
apoptosis-promoting receptor on exon definition. J Biol Chem.
283:19077–19084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N
and Khabar KS: miR-29a inhibition normalizes HuR over-expression
and aberrant AU-rich mRNA stability in invasive cancer. J Pathol.
230:28–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
López de Silanes I, Zhan M, Lal A, Yang X
and Gorospe M: Identification of a target RNA motif for RNA-binding
protein HuR. Proc Natl Acad Sci USA. 101:2987–2992. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brennan CM and Steitz JA: HuR and mRNA
stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Myer VE, Fan XC and Steitz JA:
Identification of HuR as a protein implicated in AUUUA-mediated
mRNA decay. EMBO J. 16:2130–2139. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fan XC and Steitz JA: Overexpression of
HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo
stability of ARE-containing mRNAs. EMBO J. 17:3448–3460. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Peng SS, Chen CY, Xu N and Shyu AB: RNA
stabilization by the AU-rich element binding protein, HuR, an ELAV
protein. EMBO J. 17:3461–3470. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hoch RV, Thompson DA, Baker RJ and Weigel
RJ: GATA-3 is expressed in association with estrogen receptor in
breast cancer. Int J Cancer. 84:122–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Licata LA, Hostetter CL, Crismale J, Sheth
A and Keen JC: The RNA-binding protein HuR regulates GATA3 mRNA
stability in human breast cancer cell lines. Breast Cancer Res
Treat. 122:55–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li Y, Yu J, Du D, Fu S, Chen Y, Yu F and
Gao P: Involvement of post-transcriptional regulation of FOXO1 by
HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett.
6:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang F, Miao L, Mei Y and Wu M: Retinoic
acid-induced HOXA5 expression is co-regulated by HuR and miR-130a.
Cell Signal. 25:1476–1485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rhoads K, Arderiu G, Charboneau A, Hansen
SL, Hoffman W and Boudreau N: A role for Hox A5 in regulating
angiogenesis and vascular patterning. Lymphat Res Biol. 3:240–252.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sommer S, Cui Y, Brewer G and Fuqua SA:
The c-Yes 3′-UTR contains adenine/uridine-rich elements that bind
AUF1 and HuR involved in mRNA decay in breast cancer cells. J
Steroid Biochem Mol Biol. 97:219–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Leris AC, Roberts TR, Jiang WG, Newbold RF
and Mokbel K: WNT5A expression in human breast cancer. Anticancer
Res. 25:731–734. 2005.PubMed/NCBI
|
|
55
|
Meng Z, Jackson NL, Choi H, King PH,
Emanuel PD and Blume SW: Alterations in RNA-binding activities of
IRES-regulatory proteins as a mechanism for physiological
variability and pathological dysregulation of IGF-IR translational
control in human breast tumor cells. J Cell Physiol. 217:172–183.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Scott GK, Marx C, Berger CE, Saunders LR,
Verdin E, Schäfer S, Jung M and Benz CC: Destabilization of ERBB2
transcripts by targeting 3′ untranslated region messenger RNA
associated HuR and histone deacetylase-6. Mol Cancer Res.
6:1250–1258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang W, Furneaux H, Cheng H, Caldwell MC,
Hutter D, Liu Y, Holbrook N and Gorospe M: HuR regulates p21 mRNA
stabilization by UV light. Mol Cell Biol. 20:760–769. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yan W, Zhang Y, Zhang J, Cho SJ and Chen
X: HuR is necessary for mammary epithelial cell proliferation and
polarity at least in part via ΔNp63. PLoS One. 7:e453362012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Giles KM, Daly JM, Beveridge DJ, Thomson
AM, Voon DC, Furneaux HM, Jazayeri JA and Leedman PJ: The
3′-untranslated region of p21WAF1 mRNA is a composite cis-acting
sequence bound by RNA-binding proteins from breast cancer cells,
including HuR and poly(C)-binding protein. J Biol Chem.
278:2937–2946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chock K, Allison JM and Elshamy WM:
BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and
promotes proliferation of damaged cells. Oncogene. 29:5274–5285.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Saunus JM, French JD, Edwards SL,
Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson
KJ, Francis GD, et al: Posttranscriptional regulation of the breast
cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
Cancer Res. 68:9469–9478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mazan-Mamczarz K, Hagner PR, Dai B, Wood
WH, Zhang Y, Becker KG, Liu Z and Gartenhaus RB: Identification of
transformation-related pathways in a breast epithelial cell model
using a ribonomics approach. Cancer Res. 68:7730–7735. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Suswam ES, Nabors LB, Huang Y, Yang X and
King PH: IL-1beta induces stabilization of IL-8 mRNA in malignant
breast cancer cells via the 3′ untranslated region: Involvement of
divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer.
113:911–919. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC,
Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, et al: Lapatinib-mediated
cyclooxygenase-2 expression via epidermal growth factor
receptor/HuR interaction enhances the aggressiveness of
triple-negative breast cancer cells. Mol Pharmacol. 83:857–869.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Woo HH, Zhou Y, Yi X, David CL, Zheng W,
Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB and
Chambers SK: Regulation of non-AU-rich element containing c-fms
proto-oncogene expression by HuR in breast cancer. Oncogene.
28:1176–1186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Calaluce R, Gubin MM, Davis JW, Magee JD,
Chen J, Kuwano Y, Gorospe M and Atasoy U: The RNA binding protein
HuR differentially regulates unique subsets of mRNAs in estrogen
receptor negative and estrogen receptor positive breast cancer. BMC
Cancer. 10:1262010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gubin MM, Calaluce R, Davis JW, Magee JD,
Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL and Atasoy
U: Overexpression of the RNA binding protein HuR impairs tumor
growth in triple negative breast cancer associated with deficient
angiogenesis. Cell Cycle. 9:3337–3346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yuan Z, Sanders A, Ye L, Wang Y and Jiang
WG: Prognostic value of the human antigen R (HuR) in human breast
cancer: High level predicts a favourable prognosis. Anticancer Res.
31:303–310. 2011.PubMed/NCBI
|
|
69
|
Kotta-Loizou I, Vasilopoulos SN, Coutts RH
and Theocharis S: Current evidence and future perspectives on HuR
and breast cancer development, prognosis, and treatment. Neoplasia.
18:674–688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Leandersson K, Riesbeck K and Andersson T:
Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR
in human breast epithelial cells. Nucleic Acids Res. 34:3988–3999.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhu H, Zhou HL, Hasman RA and Lou H: Hu
proteins regulate polyadenylation by blocking sites containing
U-rich sequences. J Biol Chem. 282:2203–2210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mukherjee N, Corcoran DL, Nusbaum JD, Reid
DW, Georgiev S, Hafner M, Ascano M Jr, Tuschl T, Ohler U and Keene
JD: Integrative regulatory mapping indicates that the RNA-binding
protein HuR couples pre-mRNA processing and mRNA stability. Mol
Cell. 43:327–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Akaike Y, Masuda K, Kuwano Y, Nishida K,
Kajita K, Kurokawa K, Satake Y, Shoda K, Imoto I and Rokutan K: HuR
regulates alternative splicing of the TRA2β gene in human colon
cancer cells under oxidative stress. Mol Cell Biol. 34:2857–2873.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fan XC and Steitz JA: HNS, a
nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci
USA. 95:15293–15298. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Keene JD: Why is Hu where? Shuttling of
early-response-gene messenger RNA subsets. Proc Natl Acad Sci USA.
96:5–7. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Abdelmohsen K, Srikantan S, Kuwano Y and
Gorospe M: miR-519 reduces cell proliferation by lowering
RNA-binding protein HuR levels. Proc Natl Acad Sci USA.
105:20297–20302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cabilla JP, Nudler SI, Ronchetti SA,
Quinteros FA, Lasaga M and Duvilanski BH: Nitric oxide-sensitive
guanylyl cyclase is differentially regulated by nuclear and
non-nuclear estrogen pathways in anterior pituitary gland. PLoS
One. 6:e294022011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Akool ES, Kleinert H, Hamada FM,
Abdelwahab MH, Förstermann U, Pfeilschifter J and Eberhardt W:
Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA
by inhibiting the expression of mRNA-stabilizing factor HuR. Mol
Cell Biol. 23:4901–4916. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Meisner NC, Hintersteiner M, Mueller K,
Bauer R, Seifert JM, Naegeli HU, Ottl J, Oberer L, Guenat C, Moss
S, et al: Identification and mechanistic characterization of
low-molecular-weight inhibitors for HuR. Nat Chem Biol. 3:508–515.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
D'Agostino VG, Adami V and Provenzani A: A
novel high throughput biochemical assay to evaluate the HuR
protein-RNA complex formation. PLoS One. 8:e724262013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wu X, Lan L, Wilson DM, Marquez RT, Tsao
WC, Gao P, Roy A, Turner BA, McDonald P, Tunge JA, et al:
Identification and validation of novel small molecule disruptors of
HuR-mRNA interaction. ACS Chem Biol. 10:1476–1484. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
D'Agostino VP, Lal P, Mantelli B, Tiedje
C, Zucal C, Thongon N, Gaestel M, Latorre E, Marinelli L, Seneci P,
et al: Dihydrotanshinone-I interferes with the RNA-binding activity
of HuR affecting its post-transcriptional function. Sci Rep.
5:164782015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li C, Rock KL, Woda BA, Jiang Z, Fraire AE
and Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ
of the uterine cervix: An immunohistochemical study in comparison
with p16(INK4a) expression. Mod Pathol. 20:242–247. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q,
Hsieh CC, Li C, Chen W, Duan HO, McDougal S and Wu CL: Analysis of
RNA-binding protein IMP3 to predict metastasis and prognosis of
renal-cell carcinoma: A retrospective study. Lancet Oncol.
7:556–564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Fakhraldeen SA, Clark RJ, Roopra A, Chin
EN, Huang W, Castorino J, Wisinski KB, Kim T, Spiegelman VS and
Alexander CM: Two isoforms of the RNA binding protein, coding
region determinant-binding protein (CRD-BP/IGF2BP1), are expressed
in breast epithelium and support clonogenic growth of breast tumor
cells. J Biol Chem. 290:13386–13400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Gu W, Pan F and Singer RH: Blocking
beta-catenin binding to the ZBP1 promoter represses ZBP1
expression, leading to increased proliferation and migration of
metastatic breast-cancer cells. J Cell Sci. 122:1895–1905. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Gu W, Katz Z, Wu B, Park HY, Li D, Lin S,
Wells AL and Singer RH: Regulation of local expression of cell
adhesion and motility-related mRNAs in breast cancer cells by
IMP1/ZBP1. J Cell Sci. 125:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lapidus K, Wyckoff J, Mouneimne G, Lorenz
M, Soon L, Condeelis JS and Singer RH: ZBP1 enhances cell polarity
and reduces chemotaxis. J Cell Sci. 120:3173–3178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang G, Huang Z, Liu X, Huang W, Chen S,
Zhou Y, Li D, Singer RH and Gu W: IMP1 suppresses breast tumor
growth and metastasis through the regulation of its target mRNAs.
Oncotarget. 7:15690–15702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Gu W, Wells AL, Pan F and Singer RH:
Feedback regulation between zipcode binding protein 1 and
beta-catenin mRNAs in breast cancer cells. Mol Cell Biol.
28:4963–4974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Barghash A, Helms V and Kessler SM:
Overexpression of IGF2 mRNA-binding protein 2 (IMP2/p62) as a
feature of basal-like breast cancer correlates with short survival.
Scand J Immunol. 82:142–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liu W, Li Y, Wang B, Dai L, Qian W and
Zhang JY: Autoimmune response to IGF2 mRNA-binding protein 2
(IMP2/p62) in breast cancer. Scand J Immunol. 81:502–507. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
McMullen ER, Gonzalez ME, Skala SL, Tran
M, Thomas D, Djomehri SI, Burman B, Kidwell KM and Kleer CG: CCN6
regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of
the breast. Breast Cancer Res Treat. 172:577–586. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Walter O, Prasad M, Lu S, Quinlan RM,
Edmiston KL and Khan A: IMP3 is a novel biomarker for triple
negative invasive mammary carcinoma associated with a more
aggressive phenotype. Hum Pathol. 40:1528–1533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Grimshaw MJ, Cooper L, Papazisis K,
Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou
J and Burchell JM: Mammosphere culture of metastatic breast cancer
cells enriches for tumorigenic breast cancer cells. Breast Cancer
Res. 10:R522008. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Samanta S, Sharma VM, Khan A and Mercurio
AM: Regulation of IMP3 by EGFR signaling and repression by ERβ:
Implications for triple-negative breast cancer. Oncogene.
31:4689–4697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Samanta S, Sun H, Goel HL, Pursell B,
Chang C, Khan A, Greiner DL, Cao S, Lim E, Shultz LD and Mercurio
AM: IMP3 promotes stem-like properties in triple-negative breast
cancer by regulating SLUG. Oncogene. 35:1111–1121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Phillips S, Prat A, Sedic M, Proia T,
Wronski A, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G,
et al: Cell-state transitions regulated by SLUG are critical for
tissue regeneration and tumor initiation. Stem Cell Rep. 2:633–647.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Proia TA, Keller PJ, Gupta PB, Klebba I,
Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S, et al:
Genetic predisposition directs breast cancer phenotype by dictating
progenitor cell fate. Cell Stem Cell. 8:149–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Samanta S, Guru S, Elaimy AL, Amante JJ,
Ou J, Yu J, Zhu LJ and Mercurio AM: IMP3 stabilization of WNT5B
mRNA facilitates TAZ activation in breast cancer. Cell Rep.
23:2559–2567. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hazlehurst LA, Foley NE, Gleason-Guzman
MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC and Dalton WS:
Multiple mechanisms confer drug resistance to mitoxantrone in the
human 8226 myeloma cell line. Cancer Res. 59:1021–1028.
1999.PubMed/NCBI
|
|
105
|
Samanta S, Pursell B and Mercurio AM: IMP3
protein promotes chemoresistance in breast cancer cells by
regulating breast cancer resistance protein (ABCG2) expression. J
Biol Chem. 288:12569–12573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Kim HY, Ha Thi HT and Hong S: IMP2 and
IMP3 cooperate to promote the metastasis of triple-negative breast
cancer through destabilization of progesterone receptor. Cancer
Lett. 415:30–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Rehfeld F, Rohde AM, Nguyen DT and Wulczyn
FC: Lin28 and let-7: Ancient milestones on the road from
pluripotency to neurogenesis. Cell Tissue Res. 359:145–160. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Shyh-Chang N and Daley GQ: Lin28: Primal
regulator of growth and metabolism in stem cells. Cell Stem Cell.
12:395–406. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Powers JT, Tsanov KM, Pearson DS, Roels F,
Spina CS, Ebright R, Seligson M, de Soysa Y, Cahan P, Theißen J, et
al: Multiple mechanisms disrupt the let-7 microRNA family in
neuroblastoma. Nature. 535:246–251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yao K, Qiu S, Tian L, Snider WD, Flannery
JG, Schaffer DV and Chen B: Wnt regulates proliferation and
neurogenic potential of Müller glial cells via a Lin28/let-7
miRNA-dependent pathway in adult mammalian retinas. Cell Rep.
17:165–178. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Piskounova E, Polytarchou C, Thornton JE,
LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D and Gregory RI:
Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct
mechanisms. Cell. 147:1066–1079. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gibadulinova A, Bullova P, Strnad H,
Pohlodek K, Jurkovicova D, Takacova M, Pastorekova S and Eliska
Svastoval: CAIX-mediated control of LIN28/let-7 axis contributes to
metabolic adaptation of breast cancer cells to hypoxia. Int J Mol
Sci. 21:42992020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Frost RJ and Olson EN: Control of glucose
homeostasis and insulin sensitivity by the Let-7 family of
microRNAs. Proc Natl Acad Sci USA. 108:21075–21080. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhu H, Shyh-Chang N, Segrè A, Shinoda G,
Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG,
et al: The Lin28/let-7 axis regulates glucose metabolism. Cell.
147:81–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Mayr C, Hemann MT and Bartel DP:
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic
transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sampson VB, Rong NH, Han J, Yang Q, Aris
V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA
let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt
lymphoma cells. Cancer Res. 67:9762–9770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi
JL, Shao Z, Liang S, Wang LP, Hwang WT, et al: Lin-28 homologue A
(LIN28A) promotes cell cycle progression via regulation of
cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell
division cycle 25 homolog A (CDC25A) expression in cancer. J Biol
Chem. 287:17386–17397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Isanejad A, Alizadeh AM, Amani Shalamzari
S, Khodayari H, Khodayari S, Khori V and Khojastehnjad N:
MicroRNA-206, let-7a and microRNA-21 pathways involved in the
anti-angiogenesis effects of the interval exercise training and
hormone therapy in breast cancer. Life Sci. 151:30–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Dangi-Garimella S, Yun J, Eves EM, Newman
M, Erkeland SJ, Hammond SM, Minn AJ and Rosner MR: Raf kinase
inhibitory protein suppresses a metastasis signalling cascade
involving LIN28 and let-7. EMBO J. 28:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Liu Y, Li H, Feng J, Cui X, Huang W, Li Y,
Su F, Liu Q, Zhu J, Lv X, et al: Lin28 induces
epithelial-to-mesenchymal transition and stemness via
downregulation of let-7a in breast cancer cells. PLoS One.
8:e830832013. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang L, Wang YX, Zhang DZ, Fang XJ, Sun PS
and Xue HC: Let-7a mimic attenuates CCL18 induced breast cancer
cell metastasis through Lin 28 pathway. Biomed Pharmacother.
78:301–307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Estrada-Bernal A, Chatterjee M, Haque SJ,
Yang L, Morgan MA, Kotian S, Morrell D, Chakravarti A and Williams
TM: MEK inhibitor GSK1120212-mediated radiosensitization of
pancreatic cancer cells involves inhibition of DNA double-strand
break repair pathways. Cell Cycle. 14:3713–3724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Oh JS, Kim JJ, Byun JY and Kim IA:
Lin28-let7 modulates radiosensitivity of human cancer cells with
activation of K-Ras. Int J Radiat Oncol Biol Phys. 76:5–8. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Collis SJ, Barber LJ, Clark AJ, Martin JS,
Ward JD and Boulton SJ: HCLK2 is essential for the mammalian
S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol.
9:391–401. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Teng R, Hu Y, Zhou J, Seifer B, Chen Y,
Shen J and Wang L: Overexpression of Lin28 decreases the
chemosensitivity of gastric cancer cells to oxaliplatin,
paclitaxel, doxorubicin, and fluorouracil in part via microRNA-107.
PLoS One. 10:e01437162015. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Tian N, Han Z, Li Z, Zhou M and Fan C:
Lin28/let-7/Bcl-xL pathway: The underlying mechanism of drug
resistance in Hep3B cells. Oncol Rep. 32:1050–1056. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y,
Dong M, Teng R, Wu L, Fu P, et al: Lin28 mediates paclitaxel
resistance by modulating p21, Rb and Let-7a miRNA in breast cancer
cells. PLoS One. 7:e400082012. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Okano H, Kawahara H, Toriya M, Nakao K,
Shibata S and Imai T: Function of RNA-binding protein Musashi-1 in
stem cells. Exp Cell Res. 306:349–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang XY, Penalva LQ, Yuan H, Linnoila RI,
Lu J, Okano H and Glazer RI: Musashi1 regulates breast tumor cell
proliferation and is a prognostic indicator of poor survival. Mol
Cancer. 9:2212010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Shu HJ, Saito T, Watanabe H, Ito JI,
Takeda H, Okano H and Kawata S: Expression of the Musashi1 gene
encoding the RNA-binding protein in human hepatoma cell lines.
Biochem Biophys Res Commun. 293:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Toda M, Iizuka Y, Yu W, Imai T, Ikeda E,
Yoshida K, Kawase T, Kawakami Y, Okano H and Uyemura K: Expression
of the neural RNA-binding protein Musashi1 in human gliomas. Glia.
34:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Battelli C, Nikopoulos GN, Mitchell JG and
Verdi JM: The RNA-binding protein Musashi-1 regulates neural
development through the translational repression of p21WAF-1. Mol
Cell Neurosci. 31:85–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Devgan V, Mammucari C, Millar SE, Brisken
C and Dotto GP: p21WAF1/Cip1 is a negative transcriptional
regulator of Wnt4 expression downstream of Notch1 activation. Genes
Dev. 19:1485–1495. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang XY, Yin Y, Yuan H, Sakamaki T, Okano
H and Glazer RI: Musashi1 modulates mammary progenitor cell
expansion through proliferin-mediated activation of the Wnt and
Notch pathways. Mol Cell Biol. 28:3589–3599. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Glazer RI, Vo DT and Penalva LO: Musashi1:
An RBP with versatile functions in normal and cancer stem cells.
Front Biosci (Landmark Ed). 17:54–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lindsay J, Jiao X, Sakamaki T, Casimiro
MC, Shirley LA, Tran TH, Ju X, Liu M, Li Z, Wang C, et al: ErbB2
induces Notch1 activity and function in breast cancer cells. Clin
Transl Sci. 1:107–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Choi YM, Kim KB, Lee JH, Chun YK, An IS,
An S and Bae S: DBC2/RhoBTB2 functions as a tumor suppressor
protein via Musashi-2 ubiquitination in breast cancer. Oncogene.
36:2802–2812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Baron M: An overview of the Notch
signalling pathway. Semin Cell Dev Biol. 14:113–119. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
McGill MA and McGlade CJ: Mammalian numb
proteins promote Notch1 receptor ubiquitination and degradation of
the Notch1 intracellular domain. J Biol Chem. 278:23196–23203.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wakamatsu Y, Maynard TM, Jones SU and
Weston JA: NUMB localizes in the basal cortex of mitotic avian
neuroepithelial cells and modulates neuronal differentiation by
binding to NOTCH-1. Neuron. 23:71–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Reedijk M, Odorcic S, Chang L, Zhang H,
Miller N, McCready DR, Lockwood G and Egan SE: High-level
coexpression of JAG1 and NOTCH1 is observed in human breast cancer
and is associated with poor overall survival. Cancer Res.
65:8530–8537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Ayyanan A, Civenni G, Ciarloni L, Morel C,
Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP and
Brisken C: Increased Wnt signaling triggers oncogenic conversion of
human breast epithelial cells by a Notch-dependent mechanism. Proc
Natl Acad Sci USA. 103:3799–3804. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Pece S, Serresi M, Santolini E, Capra M,
Hulleman E, Galimberti V, Zurrida S, Maisonneuve P, Viale G and Di
Fiore PP: Loss of negative regulation by Numb over Notch is
relevant to human breast carcinogenesis. J Cell Biol. 167:215–221.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hamaguchi M, Meth JL, von Klitzing C, Wei
W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC and Wigler MH:
DBC2, a candidate for a tumor suppressor gene involved in breast
cancer. Proc Natl Acad Sci USA. 99:13647–13652. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Knowles MA, Aveyard JS, Taylor CF, Harnden
P and Bass S: Mutation analysis of the 8p candidate tumour
suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer
Lett. 225:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Freeman SN and Cress WD: RhoBTB2 (DBC2)
comes of age as a multifunctional tumor suppressor. Cancer Biol
Ther. 10:1123–1125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wilkins A, Ping Q and Carpenter CL:
RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase
complex. Genes Dev. 18:856–861. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G,
Suh N, Győrffy B, Kim S, Jeong SY, Mills GB and Park YY: Musashi
RNA-binding protein 2 regulates estrogen receptor 1 function in
breast cancer. Oncogene. 36:1745–1752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Sakakibara S, Nakamura Y, Satoh H and
Okano H: Rna-binding protein Musashi2: developmentally regulated
expression in neural precursor cells and subpopulations of neurons
in mammalian CNS. J Neurosci. 21:8091–8107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Troschel FM, Minte A, Ismail YM, Kamal A,
Abdullah MS, Ahmed SH, Deffner M, Kemper B, Kiesel L, Eich HT, et
al: Knockdown of Musashi RNA binding proteins decreases
radioresistance but enhances cell motility and invasion in
triple-negative breast cancer. Int J Mol Sci. 21:21692020.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Jaggupilli A and Elkord E: Significance of
CD44 and CD24 as cancer stem cell markers: An enduring ambiguity.
Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Fang Y, Yuan Y, Zhang LL, Lu JW, Feng JF
and Hu SN: Downregulated GBX2 gene suppresses proliferation,
invasion and angiogenesis of breast cancer cells through inhibiting
the Wnt/β-catenin signaling pathway. Cancer Biomark. 23:405–418.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Peuhu E, Virtakoivu R, Mai A, Wärri A and
Ivaska J: Epithelial vimentin plays a functional role in mammary
gland development. Development. 144:4103–4113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yan W, Zhang J, Zhang Y, Jung YS and Chen
X: p73 expression is regulated by RNPC1, a target of the p53
family, via mRNA stability. Mol Cell Biol. 32:2336–2348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Xue JQ, Xia TS, Liang XQ, Zhou W, Cheng L,
Shi L, Wang Y and Ding Q: RNA-binding protein RNPC1: Acting as a
tumor suppressor in breast cancer. BMC Cancer. 14:3222014.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Feldstein O, Ben-Hamo R, Bashari D, Efroni
S and Ginsberg D: RBM38 is a direct transcriptional target of E2F1
that limits E2F1-induced proliferation. Mol Cancer Res.
10:1169–1177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zheng L, Zhang Z, Zhang S, Guo Q, Zhang F,
Gao L, Ni H, Guo X, Xiang C and Xi T: RNA binding protein RNPC1
inhibits breast cancer cell metastasis via activating
STARD13-correlated ceRNA network. Mol Pharm. 15:2123–2132. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Shu L, Yan W and Chen X: RNPC1, an
RNA-binding protein and a target of the p53 family, is required for
maintaining the stability of the basal and stress-induced p21
transcript. Genes Dev. 20:2961–2972. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Li XX, Shi L, Zhou XJ, Wu J, Xia TS, Zhou
WB, Sun X, Zhu L, Wei JF and Ding Q: The role of c-Myc-RBM38 loop
in the growth suppression in breast cancer. J Exp Clin Canc Res.
36:492017. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Shi L, Xia TS, Wei XL, Zhou W, Xue J,
Cheng L, Lou P, Li C, Wang Y, Wei JF and Ding Q: Estrogen receptor
(ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast
cancer. Oncotarget. 6:12264–12278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Lou P, Li C, Shi L, Xia TS, Zhou W, Wu J,
Zhou X, Li X, Wang Y, Wei JF and Ding Q: RNPC1 enhances
progesterone receptor functions by regulating its mRNA stability in
breast cancer. Oncotarget. 8:16387–16400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Yamada KM and Araki M: Tumor suppressor
PTEN: Modulator of cell signaling, growth, migration and apoptosis.
J Cell Sci. 114:2375–2382. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Chow LM and Baker SJ: PTEN function in
normal and neoplastic growth. Cancer Lett. 241:184–196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhou XJ, Wu J, Shi L, Li XX, Zhu L, Sun X,
Qian JY, Wang Y, Wei JF and Ding Q: PTEN expression is upregulated
by a RNA-binding protein RBM38 via enhancing its mRNA stability in
breast cancer. J Exp Clin Cancer Res. 36:1492017. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Aparicio LA, Abella V, Valladares M and
Figueroa A: Posttranscriptional regulation by RNA-binding proteins
during epithelial-to-mesenchymal transition. Cell Mol Life Sci.
70:4463–4477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Wu J, Zhou XJ, Sun X, Xia TS, Li XX, Shi
L, Zhu L, Zhou WB, Wei JF and Ding Q: RBM38 is involved in
TGF-β-induced epithelial-to-mesenchymal transition by stabilising
zonula occludens-1 mRNA in breast cancer. Br J Cancer. 117:675–684.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Cho SJ, Jung YS, Zhang J and Chen X: The
RNA-binding protein RNPC1 stabilizes the mRNA encoding the
RNA-binding protein HuR and cooperates with HuR to suppress cell
proliferation. J Biol Chem. 287:14535–14544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Lin Q, Taylor SJ and Shalloway D:
Specificity and determinants of Sam68 RNA binding. Implications for
the biological function of K homology domains. J Biol Chem.
272:27274–27280. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Chen T, Damaj BB, Herrera C, Lasko P and
Richard S: Self-association of the single-KH-domain family members
Sam68, GRP33, GLD-1, and Qk1: Role of the KH domain. Mol Cell Biol.
17:5707–5718. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Paronetto MP, Cappellari M, Busà R,
Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE and Sette C:
Alternative splicing of the cyclin D1 proto-oncogene is regulated
by the RNA-binding protein Sam68. Cancer Res. 70:229–239. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Chawla G, Lin CH, Han A, Shiue L, Ares M
Jr and Black DL: Sam68 regulates a set of alternatively spliced
exons during neurogenesis. Mol Cell Biol. 29:201–213. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Derry JJ, Richard S, Valderrama Carvajal
H, Ye X, Vasioukhin V, Cochrane AW, Chen T and Tyner AL: Sik (BRK)
phosphorylates Sam68 in the nucleus and negatively regulates its
RNA binding ability. Mol Cell Biol. 20:6114–6126. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Aubele M, Walch AK, Ludyga N, Braselmann
H, Atkinson MJ, Luber B, Auer G, Tapio S, Cooke T and Bartlett JM:
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term
survival of breast cancer patients. Br J Cancer. 99:1089–1095.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Espejo A, Côté J, Bednarek A, Richard S
and Bedford M: A protein-domain microarray identifies novel
protein-protein interactions. Biochem J. 367:697–702. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Weng Z, Thomas SM, Rickles RJ, Taylor JA,
Brauer AW, Seidel-Dugan C, Michael WM, Dreyfuss G and Brugge JS:
Identification of Src, Fyn, and Lyn SH3-binding proteins:
Implications for a function of SH3 domains. Mol Cell Biol.
14:4509–4521. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Richard S, Yu D, Blumer KJ, Hausladen D,
Olszowy MW, Connelly PA and Shaw AS: Association of p62, a
multifunctional SH2- and SH3-domain-binding protein, with src
family tyrosine kinases, Grb2, and phospholipase C gamma-1. Mol
Cell Biol. 15:186–197. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Taylor SJ, Anafi M, Pawson T and Shalloway
D: Functional interaction between c-Src and its mitotic target, Sam
68. J Biol Chem. 270:10120–10124. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Taylor SJ and Shalloway D: An RNA-binding
protein associated with Src through its SH2 and SH3 domains in
mitosis. Nature. 368:867–871. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Fumagalli S, Totty NF, Hsuan JJ and
Courtneidge SA: A target for Src in mitosis. Nature. 368:871–874.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Paronetto MP, Venables JP, Elliott DJ,
Geremia R, Rossi P and Sette C: Tr-kit promotes the formation of a
multimolecular complex composed by Fyn, PLCgamma1 and Sam68.
Oncogene. 22:8707–8715. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Paronetto MP, Achsel T, Massiello A,
Chalfant CE and Sette C: The RNA-binding protein Sam68 modulates
the alternative splicing of Bcl-x. J Cell Biol. 176:929–939. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Côté J, Boisvert FM, Boulanger MC, Bedford
MT and Richard S: Sam68 RNA binding protein is an in vivo substrate
for protein arginine N-methyltransferase 1. Mol Biol Cell.
14:274–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Bedford MT, Frankel A, Yaffe MB, Clarke S,
Leder P and Richard S: Arginine methylation inhibits the binding of
proline-rich ligands to Src homology 3, but not WW, domains. J Biol
Chem. 275:16030–16036. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Babic I, Jakymiw A and Fujita DJ: The RNA
binding protein Sam68 is acetylated in tumor cell lines, and its
acetylation correlates with enhanced RNA binding activity.
Oncogene. 23:3781–3789. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Babic I, Cherry E and Fujita DJ: SUMO
modification of Sam68 enhances its ability to repress cyclin D1
expression and inhibits its ability to induce apoptosis. Oncogene.
25:4955–4964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Barker KT, Jackson LE and Crompton MR: BRK
tyrosine kinase expression in a high proportion of human breast
carcinomas. Oncogene. 15:799–805. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Ostrander JH, Daniel AR and Lange CA:
Brk/PTK6 signaling in normal and cancer cell models. Curr Opin
Pharmacol. 10:662–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Lukong KE, Larocque D, Tyner AL and
Richard S: Tyrosine phosphorylation of sam68 by breast tumor kinase
regulates intranuclear localization and cell cycle progression. J
Biol Chem. 280:38639–38647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Lukong KE and Richard S: Sam68, the KH
domain-containing superSTAR. Biochim Biophys Acta. 1653:73–86.
2003.PubMed/NCBI
|
|
194
|
Song L, Wang L, Li Y, Xiong H, Wu J, Li J
and Li M: Sam68 up-regulation correlates with, and its
down-regulation inhibits, proliferation and tumourigenicity of
breast cancer cells. J Pathol. 222:227–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Huot ME, Brown CM, Lamarche-Vane N and
Richard S: An adaptor role for cytoplasmic Sam68 in modulating Src
activity during cell polarization. Mol Cell Biol. 29:1933–1943.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Wang Y, Zhang W, Wang X, Wang D, Xie J,
Tang C, Xi Q, Zhong J and Deng Y: Expression of Sam68 correlates
with cell proliferation and survival in epithelial ovarian cancer.
Reprod Sci. 24:97–108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Xiao J, Wang Q, Yang Q, Wang H, Qiang F,
He S, Cai J, Yang L and Wang Y: Clinical significance and effect of
Sam68 expression in gastric cancer. Oncol Lett. 15:4745–4752.
2018.PubMed/NCBI
|
|
198
|
Fu K, Sun X, Xia X, Hobbs RP, Guo Y,
Coulombe PA and Wan F: Sam68 is required for the growth and
survival of nonmelanoma skin cancer. Cancer Med. 8:6106–6113. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Huot MÉ, Vogel G, Zabarauskas A, Ngo CT,
Coulombe-Huntington J, Majewski J and Richard S: The Sam68 STAR
RNA-binding protein regulates mTOR alternative splicing during
adipogenesis. Mol Cell. 46:187–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Paez J and Sellers WR: PI3K/PTEN/AKT
pathway. A critical mediator of oncogenic signaling. Cancer Treat
Res. 115:145–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Richard S, Vogel G, Huot ME Guo T, Muller
WJ and Lukong KE: Sam68 haploinsufficiency delays onset of mammary
tumorigenesis and metastasis. Oncogene. 27:548–556. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Richard S, Torabi N, Franco GV, Tremblay
GA, Chen T, Vogel G, Morel M, Cléroux P, Forget-Richard A, Komarova
S, et al: Ablation of the Sam68 RNA binding protein protects mice
from age-related bone loss. PLoS Genet. 1:e742005. View Article : Google Scholar : PubMed/NCBI
|
